- United Therapeutics Corp (NASDAQ:UTHR) announced a preliminary analysis of the EXPEDITE Phase 4 16-week study of Remodulin induction followed by oral Orenitram optimization in patients with pulmonary arterial hypertension (PAH).
- The data demonstrated that 79% of patients in the study reached the study’s primary endpoint of a 12 mg total daily dose after an up to eight-week induction treatment period with Remodulin (treprostinil) injection.
- Also See: United Therapeutics Stops Late-Stage Tyvaso Study In Lung Disease.
- A short induction of Remodulin (treprostinil) injection allowed study subjects to reach double the typical doses of Orenitram (treprostinil) extended-release tablets than patients who did not have a Remodulin induction.
- A previous real-world dosing analysis showed an average Orenitram dose of approximately 6 mg daily after 16 weeks without the induction protocol studied by the EXPEDITE study.
- In addition, scientific literature shows that higher doses of treprostinil have been associated with better outcomes for PAH patients.
- Treatment with Orenitram, three times daily, was well tolerated, and the safety profile was consistent with previous Orenitram studies in PAH.
- Price Action: UTHR shares traded lower by 1.37% at $228.98 on the last check Monday.
How To Trade Snap Stock Before And After Q2 Earnings
Snap, Inc (NYSE: SNAP) is set to print its second-quarter financial results after the markets close on Thursday.
